FFA
NKTR icon

Farther Finance Advisors’s Nektar Therapeutics NKTR Stock Holding History

Farther Finance Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140 Buy
2
+1
+100% +$73 ﹤0.01% 5760
2026
Q1 		$76 Sell
1
-140
-99% -$7.97K ﹤0.01% 5540
2025
Q4 		$5.96K Buy
+141
New +$7.89K ﹤0.01% 4206

Other funds holding NKTR

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
G
Gainplan Bloomfield Hills, Michigan $254M AUM 25.62% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return

Farther Finance Advisors's NKTR Position: Q2 2026 in Review

Farther Finance Advisors increased its Nektar Therapeutics (NKTR) stake by 100% in Q2 2026, buying an estimated $73 and bringing the position to 2 shares worth $140. The position accounts for ﹤0.01% of the portfolio, ranked #5760.

Farther Finance Advisors first reported a position in NKTR in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.96K in Q4 2025. 11 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Farther Finance Advisors held 2 shares of Nektar Therapeutics worth $140 as of Q2 2026.
  • Farther Finance Advisors bought 1 Nektar Therapeutics share in Q2 2026, an estimated $73.
  • Nektar Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5760 holding.
  • Farther Finance Advisors first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Farther Finance Advisors's Nektar Therapeutics position peaked at $5.96K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.